GlassScriptPhysician profile
Scott R Michaels
NPI 1760514921
$1,558.90
in general payments reported to CMS, 2019-2025
20 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $155 · 2021: $255 · 2022: $205 · 2023: $232 · 2024: $338 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $401.76 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $289.29 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $163.60 | 2022-2024 | Nuzyra |
| Abbott Laboratories | $127.14 | 2021-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $99.93 | 2019 | |
| Medtronic USA, INC. | $65.68 | 2019 | |
| Inspire Medical Systems, INC. | $61.72 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $58.66 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $55.69 | 2023 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $37.52 | 2024 | Auvelity |
| Amarin Pharma, INC. | $31.72 | 2020 | |
| Pfizer INC. | $27.86 | 2025 | |
| Biogen, INC. | $22.23 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.15 | 2023 | Pyrukynd |
| Photonicare INC | $18.24 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.18 | 2024 | Mounjaro, Zepbound |
| Becton, Dickinson and Company | $18.05 | 2019 | |
| Medtronic, INC. | $13.74 | 2024 | Closurefast |
| Seqirus USA INC | $13.61 | 2019 | |
| Abbvie INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Michaels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.